137 related articles for article (PubMed ID: 16371006)
1. Unexpected similarity between the cytosolic West Nile virus NS3 and the secretory furin-like serine proteinases.
Seidah NG
Biochem J; 2006 Jan; 393(Pt 2):e1-3. PubMed ID: 16371006
[TBL] [Abstract][Full Text] [Related]
2. Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase.
Shiryaev SA; Ratnikov BI; Chekanov AV; Sikora S; Rozanov DV; Godzik A; Wang J; Smith JW; Huang Z; Lindberg I; Samuel MA; Diamond MS; Strongin AY
Biochem J; 2006 Jan; 393(Pt 2):503-11. PubMed ID: 16229682
[TBL] [Abstract][Full Text] [Related]
3. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication.
Kouretova J; Hammamy MZ; Epp A; Hardes K; Kallis S; Zhang L; Hilgenfeld R; Bartenschlager R; Steinmetzer T
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):712-721. PubMed ID: 28385094
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Macrocyclization of Substrate Analogue NS2B-NS3 Protease Inhibitors of Zika, West Nile and Dengue viruses.
Braun NJ; Quek JP; Huber S; Kouretova J; Rogge D; Lang-Henkel H; Cheong EZK; Chew BLA; Heine A; Luo D; Steinmetzer T
ChemMedChem; 2020 Aug; 15(15):1439-1452. PubMed ID: 32501637
[TBL] [Abstract][Full Text] [Related]
5. Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies.
Chappell KJ; Stoermer MJ; Fairlie DP; Young PR
J Biol Chem; 2006 Dec; 281(50):38448-58. PubMed ID: 17052977
[TBL] [Abstract][Full Text] [Related]
6. Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses.
Shiryaev SA; Kozlov IA; Ratnikov BI; Smith JW; Lebl M; Strongin AY
Biochem J; 2007 Feb; 401(3):743-52. PubMed ID: 17067286
[TBL] [Abstract][Full Text] [Related]
7. Profiling of flaviviral NS2B-NS3 protease specificity provides a structural basis for the development of selective chemical tools that differentiate Dengue from Zika and West Nile viruses.
Rut W; Groborz K; Zhang L; Modrzycka S; Poreba M; Hilgenfeld R; Drag M
Antiviral Res; 2020 Mar; 175():104731. PubMed ID: 32014497
[TBL] [Abstract][Full Text] [Related]
8. Phosphonate inhibitors of West Nile virus NS2B/NS3 protease.
Skoreński M; Milewska A; Pyrć K; Sieńczyk M; Oleksyszyn J
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):8-14. PubMed ID: 30362835
[TBL] [Abstract][Full Text] [Related]
9. West Nile Virus NS2B/NS3 protease as an antiviral target.
Chappell KJ; Stoermer MJ; Fairlie DP; Young PR
Curr Med Chem; 2008; 15(27):2771-84. PubMed ID: 18991636
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
Erbel P; Schiering N; D'Arcy A; Renatus M; Kroemer M; Lim SP; Yin Z; Keller TH; Vasudevan SG; Hommel U
Nat Struct Mol Biol; 2006 Apr; 13(4):372-3. PubMed ID: 16532006
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the West Nile virus protease substrate specificity and inhibitors.
Mueller NH; Yon C; Ganesh VK; Padmanabhan R
Int J Biochem Cell Biol; 2007; 39(3):606-14. PubMed ID: 17188926
[TBL] [Abstract][Full Text] [Related]
12. Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.
Cregar-Hernandez L; Jiao GS; Johnson AT; Lehrer AT; Wong TA; Margosiak SA
Antivir Chem Chemother; 2011 May; 21(5):209-17. PubMed ID: 21566267
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease.
Nall TA; Chappell KJ; Stoermer MJ; Fang NX; Tyndall JD; Young PR; Fairlie DP
J Biol Chem; 2004 Nov; 279(47):48535-42. PubMed ID: 15322074
[TBL] [Abstract][Full Text] [Related]
14. Miniature bovine pancreatic trypsin inhibitors (m-BPTIs) of the West Nile virus NS2B-NS3 protease.
Ang MJ; Lim HA; Poulsen A; Wee JL; Ng FM; Joy J; Hill J; Chia CS
J Enzyme Inhib Med Chem; 2016; 31(sup2):194-200. PubMed ID: 27241372
[TBL] [Abstract][Full Text] [Related]
15. Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor.
Martinez AA; Espinosa BA; Adamek RN; Thomas BA; Chau J; Gonzalez E; Keppetipola N; Salzameda NT
Eur J Med Chem; 2018 Sep; 157():1202-1213. PubMed ID: 30193218
[TBL] [Abstract][Full Text] [Related]
16. Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen.
Mueller NH; Pattabiraman N; Ansarah-Sobrinho C; Viswanathan P; Pierson TC; Padmanabhan R
Antimicrob Agents Chemother; 2008 Sep; 52(9):3385-93. PubMed ID: 18606844
[TBL] [Abstract][Full Text] [Related]
17. Mutagenesis of D80-82 and G83 residues in West Nile Virus NS2B: effects on NS2B-NS3 activity and viral replication.
Jia F; Fan J; Zhang B; Yuan Z
Virol Sin; 2013 Feb; 28(1):16-23. PubMed ID: 23325418
[TBL] [Abstract][Full Text] [Related]
18. Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation.
Robin G; Chappell K; Stoermer MJ; Hu SH; Young PR; Fairlie DP; Martin JL
J Mol Biol; 2009 Feb; 385(5):1568-77. PubMed ID: 19059417
[TBL] [Abstract][Full Text] [Related]
19. Homology modeling and molecular dynamics study of West Nile virus NS3 protease: a molecular basis for the catalytic activity increased by the NS2B cofactor.
Zhou H; Singh NJ; Kim KS
Proteins; 2006 Nov; 65(3):692-701. PubMed ID: 16972281
[TBL] [Abstract][Full Text] [Related]
20. Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis.
Shiryaev SA; Ratnikov BI; Aleshin AE; Kozlov IA; Nelson NA; Lebl M; Smith JW; Liddington RC; Strongin AY
J Virol; 2007 May; 81(9):4501-9. PubMed ID: 17301157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
